Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion

Summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK41959 when given orally in patients with MTAP Deletion locally advanced or metastatic Solid Tumors.

Timeline

Start

2025-04-11

Primary completion

2026-03-26

Completion

2028-05-08

Drugs

Indications